Checked
Veru Inc.
Nasdaq: VERU · Pharmaceutical Preparations · Miami, FL
- Net income
- -$22.73M
- Total assets
- $29.84M
- Diluted EPS
- -$1.55
Company details
As reported to the SEC
- SEC CIK
- 863894
- Stock
- Nasdaq: VERU
- Legal Entity Identifier (LEI)
- 529900ER63TFLEIJV631
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 2916 N. Miami Avenue, Suite 1000, Miami, FL 33127
- Incorporated in
- Wisconsin
- Fiscal year end (SEC record)
- September 30
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (312) 595-9123
- Employer ID (EIN)
- 39-1144397
- Last annual report
- 12/17/2025
- Last quarterly report
- 08/10/2026
Formerly: FEMALE HEALTH CO (until 08/01/2017)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 09/30/2025 | 09/30/2024 | 09/30/2023 | 09/30/2022 | 09/30/2021 |
|---|---|---|---|---|---|
| Revenue | Not reported | $16.89M | $16.3M | $39.35M | $61.26M |
| Gross profit | Not reported | $5.85M | $7.57M | $30.59M | $47.93M |
| Operating income | -$24.75M | -$36.17M | -$93.78M | -$83.49M | $12.97M |
| Net income | -$22.73M | -$37.8M | -$93.15M | -$84.04M | $7.39M |
| Diluted earnings per share | -$1.55 | -$2.80 | -$1.10 | -$1.05 | $0.09 |
| Research and development | $15.59M | $12.78M | $51.2M | $70.91M | $32.69M |
| Total assets | $29.84M | $60.42M | $50.02M | $135.4M | $178.1M |
| Total liabilities | $11.5M | $28.1M | $30.34M | $52.56M | $25.85M |
| Shareholders' equity | $18.33M | $32.32M | $19.68M | $82.8M | $154.5M |
| Cash and cash equivalents | $15.79M | $24.92M | $9.63M | Not reported | Not reported |
| Cash from operations | -$30.04M | -$21.68M | -$88.01M | -$47.51M | -$15.57M |
| Capital expenditures | $1.08K | $158.3K | $665.7K | $733.1K | $376.6K |
Subsidiaries
3 companies that Veru Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Aspen Park Pharmaceuticals, Inc. | SEC 10-K |
| Badger Acquisition Sub, Inc. | SEC 10-K |
| PCHC Limited | SEC 10-K |
Recent filings
153 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KOther events | 09/08/2026 | 09/08/2026 |
| 10-QQuarterly report | 08/10/2026 | 06/30/2026 |
| 8-KResults of operations | 08/10/2026 | 08/10/2026 |
| 8-KMaterial agreement | 07/02/2026 | 07/02/2026 |
| 424B5Prospectus supplement | 07/02/2026 | None |
| 8-KOther events | 06/04/2026 | 06/02/2026 |
| S-8Registration of employee stock plan shares | 05/13/2026 | None |
| 10-QQuarterly report | 05/13/2026 | 03/31/2026 |
| 8-KResults of operations | 05/13/2026 | 05/13/2026 |
| EFFECTNotice of effectiveness | 04/15/2026 | None |
| EFFECTNotice of effectiveness | 04/15/2026 | None |
| CORRESPLetter to the SEC staff | 04/13/2026 | None |
| CORRESPLetter to the SEC staff | 04/13/2026 | None |
| UPLOADLetter from the SEC staff | 04/13/2026 | None |
| UPLOADLetter from the SEC staff | 04/13/2026 | None |
| S-3Shelf registration statement | 04/07/2026 | None |
| S-3Shelf registration statement | 04/07/2026 | None |
| 8-KDirector or officer change, Shareholder vote results | 03/13/2026 | 03/12/2026 |
| SCHEDULE 13GOwnership report (5% holder, passive) | 02/17/2026 | None |
| 10-QQuarterly report | 02/11/2026 | 12/31/2025 |
17 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Veru Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Veru Inc.'s CIK number?
- Veru Inc.'s SEC Central Index Key (CIK) is 863894.
- What is Veru Inc.'s stock ticker?
- Veru Inc. trades as Nasdaq: VERU.
- When does Veru Inc.'s fiscal year end?
- Veru Inc.'s fiscal year end on file with the SEC is September 30; its most recent fiscal year ended Sep 30, 2025.
- Where is Veru Inc. headquartered?
- Veru Inc.'s principal executive office on file with the SEC is in Miami, FL.
- What companies does Veru Inc. own?
- Veru Inc. lists 3 subsidiaries in its SEC filings and other public records, including Aspen Park Pharmaceuticals, Inc., Badger Acquisition Sub, Inc., PCHC Limited.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026